BACKGROUND: Short QT (SQT) syndrome (SQT) 1 is an inherited sudden death syndrome often associated with atrial fibrillation (AF). We examined the cellular basis for AF in a newly developed experimental atrial model of SQT1. METHODS: Action potentials (APs) were recorded from the pectinate muscle (PM) and crista terminalis (CT) regions of coronary-perfused canine right atrial preparations, together with a pseudoelectrocardiogram. The I(Kr) agonist PD-118057 (20 microM) was used to mimic the gain of function in I(Kr) known to underlie SQT1. RESULTS: The I(Kr) agonist significantly abbreviated the AP duration (APD) of CT and PM and of the effective refractory period (ERP) measured in PM (n = 28). Spatial dispersion of repolarization (SDR), defined as inter-regional differences of APD, increased from 27 +/- 17 ms to 51 +/- 32 ms (P = .002; n = 28). AF could be induced by a single premature stimulus after but not before exposure to PD-118057 in 26/28 (93%) preparations. Quinidine (10 microM), which prolonged APD and ERP, but not lidocaine (20 microM) or E-4031 (5 microM), which prolonged only ERP or APD, respectively, was effective in preventing the PD-118057-mediated AF. In the presence of PD-118057, isoproterenol (100 nM) further abbreviated both APD and ERP and facilitated induction of sustained AF in five of six preparations. CONCLUSIONS: The I(Kr) agonist recapitulates the electrophysiologic and arrhythmic manifestations of SQT1. Abbreviation of APD and ERP and amplification of SDR predispose to the development of AF by creating the substrate for reentry. Quinidine, but not E-4031 or lidocaine, was effective in preventing AF in this setting.
BACKGROUND:Short QT (SQT) syndrome (SQT) 1 is an inherited sudden death syndrome often associated with atrial fibrillation (AF). We examined the cellular basis for AF in a newly developed experimental atrial model of SQT1. METHODS: Action potentials (APs) were recorded from the pectinate muscle (PM) and crista terminalis (CT) regions of coronary-perfused canine right atrial preparations, together with a pseudoelectrocardiogram. The I(Kr) agonist PD-118057 (20 microM) was used to mimic the gain of function in I(Kr) known to underlie SQT1. RESULTS: The I(Kr) agonist significantly abbreviated the AP duration (APD) of CT and PM and of the effective refractory period (ERP) measured in PM (n = 28). Spatial dispersion of repolarization (SDR), defined as inter-regional differences of APD, increased from 27 +/- 17 ms to 51 +/- 32 ms (P = .002; n = 28). AF could be induced by a single premature stimulus after but not before exposure to PD-118057 in 26/28 (93%) preparations. Quinidine (10 microM), which prolonged APD and ERP, but not lidocaine (20 microM) or E-4031 (5 microM), which prolonged only ERP or APD, respectively, was effective in preventing the PD-118057-mediated AF. In the presence of PD-118057, isoproterenol (100 nM) further abbreviated both APD and ERP and facilitated induction of sustained AF in five of six preparations. CONCLUSIONS: The I(Kr) agonist recapitulates the electrophysiologic and arrhythmic manifestations of SQT1. Abbreviation of APD and ERP and amplification of SDR predispose to the development of AF by creating the substrate for reentry. Quinidine, but not E-4031 or lidocaine, was effective in preventing AF in this setting.
Authors: Michel Haïssaguerre; Prashanthan Sanders; Mélèze Hocini; Yoshihide Takahashi; Martin Rotter; Frederic Sacher; Thomas Rostock; Li-Fern Hsu; Pierre Bordachar; Sylvain Reuter; Raymond Roudaut; Jacques Clémenty; Pierre Jaïs Journal: J Cardiovasc Electrophysiol Date: 2005-11
Authors: Christian Wolpert; Rainer Schimpf; Carla Giustetto; Charles Antzelevitch; Jonathan Cordeiro; Robert Dumaine; Ramon Brugada; Kui Hong; Urs Bauersfeld; Fiorenzo Gaita; Martin Borggrefe Journal: J Cardiovasc Electrophysiol Date: 2005-01
Authors: Ramon Brugada; Kui Hong; Robert Dumaine; Jonathan Cordeiro; Fiorenzo Gaita; Martin Borggrefe; Teresa M Menendez; Josep Brugada; Guido D Pollevick; Christian Wolpert; Elena Burashnikov; Kiyotaka Matsuo; Yue Sheng Wu; Alejandra Guerchicoff; Francesca Bianchi; Carla Giustetto; Rainer Schimpf; Pedro Brugada; Charles Antzelevitch Journal: Circulation Date: 2003-12-15 Impact factor: 29.690
Authors: José M Di Diego; Serge Sicouri; Rachel C Myles; Francis L Burton; Godfrey L Smith; Charles Antzelevitch Journal: J Mol Cell Cardiol Date: 2012-11-09 Impact factor: 5.000
Authors: Peter J Schwartz; Michael J Ackerman; Charles Antzelevitch; Connie R Bezzina; Martin Borggrefe; Bettina F Cuneo; Arthur A M Wilde Journal: Nat Rev Dis Primers Date: 2020-07-16 Impact factor: 52.329
Authors: David M German; Muammar M Kabir; Thomas A Dewland; Charles A Henrikson; Larisa G Tereshchenko Journal: Ann Noninvasive Electrocardiol Date: 2015-11-02 Impact factor: 1.468